×

Business / Stock Market

Astellas Pharma, Seagen: Japan's MHLW Oks PADCEV For Advanced Urothelial Cancer

Published Sep 27 2021 at 7:40 AM GMT

Business Insider

Business Insider @businessinsider.com

Add to Collections
Report Post

Continue reading at businessinsider.com

Key
Points

(RTTNews) - Japan's Astellas Pharma Inc.
(SGEN) announced Monday that PADCEV (enfortumab vedotin) has received approval from Japan's Ministry of Health, Labour and Welfare or MHLW.
The approval is for radically unresectable urothelial carcinoma that has progressed after anti-cancer chemotherapy.

Credit

Tags

Continue reading at businessinsider.com

Posted in Business, Stock Market

Stats

Published Sep 27, 2021 7:40 AM GMT